In the head-to-head phase 3 TRANSCEND-T2D-2 trial, the investigational triple agonist achieved superior HbA1c reduction and more than double the weight loss of semaglutide 2mg at week 80.

First interim analysis of the phase 3 LiGeR-HN1 trial shows significant improvements in overall survival and objective response rate with petosemtamab plus pembrolizumab vs pembrolizumab alone in ...

Total naloxone administrations and layperson-administered naloxone administration were below projected levels.

HealthDay News — Dengue cases in Florida keep climbing about a month after 3 counties declared states of emergency over the ...

All PROs significantly higher for those discontinuing TNFi at week 12 vs week 0, but not at later time points.

Compared with the placebo group, the 400mg group had significantly higher percentages of participants with clinical remission at week 12. HealthDay News — For patients with moderately to severely ...

HealthDay News — Early uptake was rapid for oral semaglutide (Wegovy pill) relative to injectable incretin-based weight ...

Adults with moderately to severely active Crohn disease can now self-administer risankizumab induction at home using an ...

Interim data from the open-label phase 3 MagnetisMM-32 study demonstrate a significant progression free survival benefit with elranatamab monotherapy vs active standard regimens in patients previously ...

HealthDay News — For patients with atrial fibrillation (AF) and prior intracranial bleeding, direct oral anticoagulants (DOACs) are associated with a reduced risk for ischemic stroke (IS) and death, ...

HealthDay News — More than half of children younger than 5 years exposed to hepatitis B virus (HBV) are exposed by someone in their household other than their birth mother, according to a study ...

Topline phase 3 data show tradipitant significantly reduced semaglutide-associated vomiting and severe nausea in adults with ...